261 related articles for article (PubMed ID: 7044633)
1. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.
Bernstein RM; Steigerwald JC; Tan EM
Clin Exp Immunol; 1982 Apr; 48(1):43-51. PubMed ID: 7044633
[TBL] [Abstract][Full Text] [Related]
2. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.
Tan EM; Rodnan GP; Garcia I; Moroi Y; Fritzler MJ; Peebles C
Arthritis Rheum; 1980 Jun; 23(6):617-25. PubMed ID: 6155920
[TBL] [Abstract][Full Text] [Related]
3. Antinuclear antibodies in progressive systemic sclerosis.
Riboldi P; Asero R; Origgi L; Crespi S; Meroni PL; Sguotti C; Sabbadini MG
Clin Exp Rheumatol; 1985; 3(3):205-11. PubMed ID: 3902296
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of antinuclear antibodies in progressive systemic sclerosis].
Scagliusi P; De Lucia M; Di Luca ML; Pannarale M; Pipitone V
Minerva Med; 1984 Feb; 75(5):161-6. PubMed ID: 6366619
[TBL] [Abstract][Full Text] [Related]
5. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
Fritzler MJ; Kinsella TD
Am J Med; 1980 Oct; 69(4):520-6. PubMed ID: 6968511
[TBL] [Abstract][Full Text] [Related]
6. Antinuclear antibodies as immunologic markers for a benign subset and different clinical characteristics of scleroderma.
Kleinsmith DM; Heinzerling RH; Burnham TK
Arch Dermatol; 1982 Nov; 118(11):882-5. PubMed ID: 6753766
[TBL] [Abstract][Full Text] [Related]
7. [Centromere antibodies and antibodies against Scl 70 nucleoprotein in progressive systemic scleroderma. Diagnostic and prognostic significance].
Meurer M; Scharf A; Luderschmidt C; Braun-Falco O
Dtsch Med Wochenschr; 1985 Jan; 110(1):8-14. PubMed ID: 3880700
[TBL] [Abstract][Full Text] [Related]
8. Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration.
Furst DE; Clements PJ; Saab M; Sterz MG; Paulus HE
Ann Rheum Dis; 1984 Dec; 43(6):794-801. PubMed ID: 6335385
[TBL] [Abstract][Full Text] [Related]
9. Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.
McCarty GA; Rice JR; Bembe ML; Barada FA
Arthritis Rheum; 1983 Jan; 26(1):1-7. PubMed ID: 6337593
[TBL] [Abstract][Full Text] [Related]
10. [Anti-Scl-70 antibodies in systemic scleroderma].
Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
[TBL] [Abstract][Full Text] [Related]
11. [Anti-centromere antibody, biological marker of the CREST syndrome as distinct from scleroderma].
Rouquette-Gally AM; Stern MH; Prost AC; Abuaf N; Homberg JC; Combrisson A
Presse Med; 1985 Jul 13-20; 14(28):1497-500. PubMed ID: 2931679
[TBL] [Abstract][Full Text] [Related]
12. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
[TBL] [Abstract][Full Text] [Related]
13. Scl 70 antibody--a specific marker of systemic sclerosis.
Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
[TBL] [Abstract][Full Text] [Related]
14. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies.
Cassani F; Tosti A; Bianchi FB; Fusconi M; Selleri L; Baffoni L; Veronesi S; Volta U; Lenzi M; Pisi E
Clin Exp Rheumatol; 1987; 5(1):23-8. PubMed ID: 3109797
[TBL] [Abstract][Full Text] [Related]
15. [The fibrillarin (Scl-34) autoantibody in systemic scleroderma].
Kühn G; Jarzabek-Chorzelska M; Blaszczyk M; Chorzelski TP; Jablonska S
Dermatol Monatsschr; 1990; 176(1):19-26. PubMed ID: 2178987
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension in the CREST syndrome: variant of systemic sclerosis (scleroderma)--a case report.
Lie JT
Angiology; 1989 Aug; 40(8):764-7. PubMed ID: 2757266
[TBL] [Abstract][Full Text] [Related]
17. Serological markers in progressive systemic sclerosis: clinical correlations.
Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
[TBL] [Abstract][Full Text] [Related]
18. [The clinical spectrum of patients with anticentromere antibodies].
Insua Vilariño S; de la Hera Martínez M; Rodríguez-Valverde V; Merino Pérez J; Alonso Valdivieso JL; Ruiz T
Rev Clin Esp; 1993 Apr; 192(6):260-4. PubMed ID: 8497719
[TBL] [Abstract][Full Text] [Related]
19. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
Kallenberg CG; Pastoor GW; Wouda AA; The TH
Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
[TBL] [Abstract][Full Text] [Related]
20. Studies of antinuclear antibodies in rheumatoid arthritis.
Garcia-de la Torre I; Miranda-Mendez L
J Rheumatol; 1982; 9(4):603-6. PubMed ID: 6182293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
